Patents Represented by Attorney, Agent or Law Firm Scott L. Ausenhus
-
Patent number: 8333963Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.Type: GrantFiled: August 4, 2010Date of Patent: December 18, 2012Assignee: Immunex CorporationInventors: Dirk M Anderson, Laurent J Galibert
-
Patent number: 8288339Abstract: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.Type: GrantFiled: April 20, 2007Date of Patent: October 16, 2012Assignee: Amgen Inc.Inventors: Colin Victor Gegg, Jr., Leslie Phillip Miranda, Katherine Ann Winters, Murielle Veniant-Ellison
-
Patent number: 8182813Abstract: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.Type: GrantFiled: August 20, 2008Date of Patent: May 22, 2012Assignee: Amgen Inc.Inventors: Kenneth Allan Brasel, James F. Smothers, Douglas Pat Cerretti
-
Patent number: 8153775Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: GrantFiled: April 22, 2011Date of Patent: April 10, 2012Assignee: Immunex CorporationInventor: Dirk M Anderson
-
Patent number: 7932375Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: GrantFiled: July 30, 2007Date of Patent: April 26, 2011Assignee: Immunex CorporationInventor: Dirk M Anderson
-
Patent number: 7790684Abstract: Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.Type: GrantFiled: June 11, 2008Date of Patent: September 7, 2010Assignee: Immunex CorporationInventors: Dirk M. Anderson, Laurent J. Galibert
-
Patent number: 7744886Abstract: Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.Type: GrantFiled: June 24, 2008Date of Patent: June 29, 2010Assignee: Immunex CorporationInventor: Dirk M Anderson
-
Patent number: 7723478Abstract: Disclosed are nucleic acid molecules encoding novel DKR polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.Type: GrantFiled: August 14, 2007Date of Patent: May 25, 2010Assignee: Amgen Inc.Inventors: Michael Brian Bass, John Kevin Sullivan, Lars Eyde Theill, Daguang Wang
-
Patent number: 7709611Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.Type: GrantFiled: August 4, 2005Date of Patent: May 4, 2010Assignee: Amgen Inc.Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
-
Patent number: 7662376Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.Type: GrantFiled: December 27, 2006Date of Patent: February 16, 2010Assignee: Amgen Inc.Inventors: Hui Tian, Joshua Schultz, Bei Shan
-
Patent number: 7572594Abstract: The present invention provides methods for screening for a molecule that antagonizes or agonizes RANK activity. One aspect of the invention involves the growth of RANK responsive cells in semi-solid medium, wherein exposure to a RANK antagonist promotes colony formation. Other aspects of the invention rely on promoter/reporter constructs using RANK responsive promoters derived from the MMP-9 and TRAP genes. Additional aspects of the invention exploit the ability of RANK to activate c-src activity, F-actin ring formation and CaPO4 resorption.Type: GrantFiled: April 4, 2005Date of Patent: August 11, 2009Assignee: Immunex CorporationInventor: William C. Dougall
-
Patent number: 7446181Abstract: The invention relates to antibodies and immunologically active portions thereof that selectively bind a human Dickkopf-1 (Dkk-1) or Dkk-1-related polypeptide, and to compositions that contain such antibodies and/or immunologically active portions.Type: GrantFiled: April 6, 2004Date of Patent: November 4, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Sean A. McCarthy
-
Patent number: 7411050Abstract: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.Type: GrantFiled: March 16, 2004Date of Patent: August 12, 2008Assignee: Immunex CorporationInventor: Dirk M. Anderson
-
Patent number: 7405270Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.Type: GrantFiled: July 19, 2002Date of Patent: July 29, 2008Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
-
Patent number: 7262274Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: GrantFiled: April 1, 2003Date of Patent: August 28, 2007Assignee: Immunex CorporationInventor: Dirk M. Anderson
-
Patent number: 7057017Abstract: Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 4, 2001Date of Patent: June 6, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventor: Sean A. McCarthy
-
Patent number: 6808880Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.Type: GrantFiled: January 19, 2001Date of Patent: October 26, 2004Assignees: Geron Corporation, Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin Harley, William H. Andrews
-
Patent number: 6617110Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: November 24, 2000Date of Patent: September 9, 2003Assignees: Geron Corporation, University Technology CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6475789Abstract: The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.Type: GrantFiled: August 14, 1997Date of Patent: November 5, 2002Assignees: University Technology Corporation, Geron CorporationInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 6287874Abstract: The present invention provides a variety of methods of analyzing protein binding events using a system capable of directly detecting protein/ligand complexes based upon the dielectric properties of the complex. The system can be used in a variety of analyses involving protein binding events, such as screening ligand libraries, characterizing protein binding interactions, and identifying ligands. The system can also be utilized in diverse analytical and diagnostic applications.Type: GrantFiled: August 2, 1999Date of Patent: September 11, 2001Assignee: Signature BioScience, Inc.Inventor: John Hefti